Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination With Standard Chemotherapy in Patients With Advanced and/or Treatment-Refractory Solid Tumors

Trial Profile

Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination With Standard Chemotherapy in Patients With Advanced and/or Treatment-Refractory Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Dec 2016

At a glance

  • Drugs CB 839 (Primary) ; Docetaxel; Erlotinib; Everolimus; Paclitaxel
  • Indications Advanced breast cancer; Breast cancer; Gastrointestinal stromal tumours; Mesothelioma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Calithera Biosciences
  • Most Recent Events

    • 02 Dec 2016 Results assessing efficacy and safety of the combination of CB-839 and everolimus from patients with previously treated advanced/metastatic clear cell and papillary renal cell cancer (n=10) presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
    • 09 Nov 2016 According to Clathira Biosciences media release, data from the study focusing on CB-839 in combination with paclitaxel in patients with triple negative breast cancer will be presented at the San Antonio Breast Cancer Symposium.
    • 09 Sep 2016 According to a Calithera Biosciences media release, results from this trial focussing on CB-839 in combination with everolimus in patients with clear cell and papillary renal cell carcinoma will be presented at the 28th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top